MRNA closed September at $154.27 — a stock that has tripled in six weeks, yet still sits below where most of the analysts who just raised their targets told clients to sell.
The most notable development this week was not in the short book. It was on the Street. A wave of analyst actions washed through over five trading days, and the direction was unambiguous: targets moved up, sharply. Goldman Sachs lifted its target from $67 to $120. UBS moved from $50 to $150. Barclays pushed from $48 to $125. JP Morgan, still bearish on the rating, nonetheless doubled its target from $40 to $77. The pattern is consistent: the bulls and the neutrals both chased the stock higher on paper, while the positioning — Underweight at JP Morgan, Equal-Weight at Barclays and Morgan Stanley — barely moved. Argus Research was the week's outlier, upgrading to Buy with a $180 target, making it the most constructive call in the group. The mean price target now sits at roughly $113. Against a $154 stock, that implies the consensus still sees downside — a rare setup where the Street has spent a week raising numbers and still hasn't caught the price.
The short book is consistent with the picture laid out in recent notes: large, stubborn, and not capitulating. Short interest edged up 3.9% over the trailing week to approximately 50.4 million shares, or 12.9% of the free float — essentially flat with the pre-INTerpath-001 level. Bears who did not cover into the August rally have not been forced out. The ORTEX short score has retreated to 57.4 from 65.6 two weeks ago, reflecting some easing of squeeze dynamics, but the absolute position is unchanged. The borrow market supports this read: availability has loosened materially, now running at 405%, the widest level in the 30-day window and well above the 52-week floor near 196%. More than four shares sit unlent for every one borrowed. Cost to borrow has edged up slightly — around 0.55%, up roughly 5% on the week — but remains negligible. The short side has plenty of room to grow if conviction deepens.
Options sentiment has shifted, and that shift is worth naming directly. The put/call ratio stood at a 52-week high of 1.51 the week of August 20. It has since cooled to 1.24, near its 20-day average of 1.27 and with a z-score close to zero. That is a meaningful reversal of the defensive panic that characterised the immediate post-catalyst period. Options traders are no longer loading up on downside protection at the rate they were. Whether that reflects growing comfort with the new price level, or simply exhaustion after a week of heavy hedging activity, the signal is that the acute fear trade has faded.
Institutional flow adds texture. FMR (Fidelity) added roughly 6.1 million shares in the period through July 31, lifting its stake to 13.1% of the company — the largest single institutional position. Capital Research also added 3.6 million shares in the same window, crossing 5% and filing a fresh 13G in August. Baillie Gifford trimmed its position from 5.3% to 4.6%, just below the reporting threshold; per standard disclosure rules, it may not file again if it continues to reduce. CEO Stéphane Bancel holds 5.6% of the company and added a modest 252,000 shares through early August. The insider activity in the most recent filings — small option exercises and associated tax withholding by the CFO, President, and CLO on August 27-28 — are routine compensation mechanics rather than directional signals. Net insider activity over 90 days is flat.
Peers have broadly struggled while Moderna held its ground. BNTX fell 10.6% over the trailing week. TWST dropped 12.8%. ARCT was the exception, gaining 5% on the week and matching Moderna's 9.9% single-day gain on September 1. The broader mRNA and gene-therapy space remains under pressure. Moderna's relative resilience — down just 2.9% on the week, even with the $3 billion convertible note overhang — continues to stand out against that backdrop.
The next scheduled catalyst is Q3 earnings on November 5. Between now and then, the unresolved question is whether the analyst consensus — still implying downside from current levels even after a week of aggressive target raises — begins to converge toward the price, or whether the price converges toward the consensus.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
